questionsmedicales.fr
Maladies du système immunitaire
Hypersensibilité
Hypersensibilité retardée
Hypersensibilité retardée : Questions médicales fréquentes
Termes MeSH sélectionnés :
G2 Phase Cell Cycle Checkpoints
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Hypersensibilité retardée : Questions médicales les plus fréquentes",
"headline": "Hypersensibilité retardée : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Hypersensibilité retardée : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-04-04",
"dateModified": "2025-03-30",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Hypersensibilité retardée"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Hypersensibilité",
"url": "https://questionsmedicales.fr/mesh/D006967",
"about": {
"@type": "MedicalCondition",
"name": "Hypersensibilité",
"code": {
"@type": "MedicalCode",
"code": "D006967",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C20.543"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Eczéma de contact allergique",
"alternateName": "Dermatitis, Allergic Contact",
"url": "https://questionsmedicales.fr/mesh/D017449",
"about": {
"@type": "MedicalCondition",
"name": "Eczéma de contact allergique",
"code": {
"@type": "MedicalCode",
"code": "D017449",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C20.543.418.150"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Dermatite photoallergique",
"alternateName": "Dermatitis, Photoallergic",
"url": "https://questionsmedicales.fr/mesh/D017454",
"about": {
"@type": "MedicalCondition",
"name": "Dermatite photoallergique",
"code": {
"@type": "MedicalCode",
"code": "D017454",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C20.543.418.150.600"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Dermatite de contact au Rhus toxicodendron",
"alternateName": "Dermatitis, Toxicodendron",
"url": "https://questionsmedicales.fr/mesh/D011040",
"about": {
"@type": "MedicalCondition",
"name": "Dermatite de contact au Rhus toxicodendron",
"code": {
"@type": "MedicalCode",
"code": "D011040",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C20.543.418.150.700"
}
}
}
]
},
{
"@type": "MedicalWebPage",
"name": "Sarcoïdose",
"alternateName": "Sarcoidosis",
"url": "https://questionsmedicales.fr/mesh/D012507",
"about": {
"@type": "MedicalCondition",
"name": "Sarcoïdose",
"code": {
"@type": "MedicalCode",
"code": "D012507",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C20.543.418.575"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Sarcoïdose pulmonaire",
"alternateName": "Sarcoidosis, Pulmonary",
"url": "https://questionsmedicales.fr/mesh/D017565",
"about": {
"@type": "MedicalCondition",
"name": "Sarcoïdose pulmonaire",
"code": {
"@type": "MedicalCode",
"code": "D017565",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C20.543.418.575.725"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Uvéoparotidite",
"alternateName": "Uveoparotid Fever",
"url": "https://questionsmedicales.fr/mesh/D014608",
"about": {
"@type": "MedicalCondition",
"name": "Uvéoparotidite",
"code": {
"@type": "MedicalCode",
"code": "D014608",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C20.543.418.575.865"
}
}
}
]
}
],
"about": {
"@type": "MedicalCondition",
"name": "Hypersensibilité retardée",
"alternateName": "Hypersensitivity, Delayed",
"code": {
"@type": "MedicalCode",
"code": "D006968",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Elizabeth J Phillips",
"url": "https://questionsmedicales.fr/author/Elizabeth%20J%20Phillips",
"affiliation": {
"@type": "Organization",
"name": "Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA. Elizabeth.j.phillips@vumc.org."
}
},
{
"@type": "Person",
"name": "Shuen-Iu Hung",
"url": "https://questionsmedicales.fr/author/Shuen-Iu%20Hung",
"affiliation": {
"@type": "Organization",
"name": "Cancer Vaccine & Immune Cell Therapy Core Lab, Department of Medical Research, Chang Gung Memorial Hospital, Linkou Branch, No. 5, Fuxing St., Guishan Dist., Taoyuan 333, Taiwan; Department of Dermatology, Drug Hypersensitivity Clinical and Research Center, Chang Gung Memorial Hospital, Linkou Branch, No. 5, Fuxing St., Guishan Dist., Taoyuan 333, Taiwan; Department and Institute of Pharmacology, National Yang Ming Chiao Tung University, No.155, Sec.2, Linong Street, Taipei, 112 Taiwan. Electronic address: sihung@cgmh.org.tw."
}
},
{
"@type": "Person",
"name": "Andrew Gibson",
"url": "https://questionsmedicales.fr/author/Andrew%20Gibson",
"affiliation": {
"@type": "Organization",
"name": "Immunology and Infectious Diseases, Murdoch University, Murdoch, WA, Australia."
}
},
{
"@type": "Person",
"name": "Chuang-Wei Wang",
"url": "https://questionsmedicales.fr/author/Chuang-Wei%20Wang",
"affiliation": {
"@type": "Organization",
"name": "Cancer Vaccine & Immune Cell Therapy Core Lab, Department of Medical Research, Chang Gung Memorial Hospital, Linkou Branch, No. 5, Fuxing St., Guishan Dist., Taoyuan 333, Taiwan; Department of Dermatology, Drug Hypersensitivity Clinical and Research Center, Chang Gung Memorial Hospital, Linkou Branch, No. 5, Fuxing St., Guishan Dist., Taoyuan 333, Taiwan; Department of Dermatology, Xiamen Chang Gung Hospital, No. 123, Xiafei Road, Haicang District, Xiamen, China."
}
},
{
"@type": "Person",
"name": "Wen-Hung Chung",
"url": "https://questionsmedicales.fr/author/Wen-Hung%20Chung",
"affiliation": {
"@type": "Organization",
"name": "Cancer Vaccine & Immune Cell Therapy Core Lab, Department of Medical Research, Chang Gung Memorial Hospital, Linkou Branch, No. 5, Fuxing St., Guishan Dist., Taoyuan 333, Taiwan; Department of Dermatology, Drug Hypersensitivity Clinical and Research Center, Chang Gung Memorial Hospital, Linkou Branch, No. 5, Fuxing St., Guishan Dist., Taoyuan 333, Taiwan; Department of Dermatology, Xiamen Chang Gung Hospital, No. 123, Xiafei Road, Haicang District, Xiamen, China; Whole-Genome Research Core Laboratory of Human Diseases, Chang Gung Memorial Hospital, Keelung Branch, No. 222, Maijin Rd., Anle Dist., Keelung 204, Taiwan; College of Medicine, Chang Gung University, No.259, Wenhua 1st Rd., Guishan Dist., Taoyuan 333, Taiwan. Electronic address: chung1@cgmh.org.tw."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Andrographolide Induces G2/M Cell Cycle Arrest and Apoptosis in Human Glioblastoma DBTRG-05MG Cell Line via ERK1/2 /c-Myc/p53 Signaling Pathway.",
"datePublished": "2022-10-08",
"url": "https://questionsmedicales.fr/article/36235222",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3390/molecules27196686"
}
},
{
"@type": "ScholarlyArticle",
"name": "Pan-cancer antagonistic inhibition pattern of ATM-driven G2/M checkpoint pathway vs other DNA repair pathways.",
"datePublished": "2023-01-13",
"url": "https://questionsmedicales.fr/article/36657260",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.dnarep.2023.103448"
}
},
{
"@type": "ScholarlyArticle",
"name": "Glycan analysis of Lamin A/C protein at G2/M and S phases of the cell cycle.",
"datePublished": "2022-09-30",
"url": "https://questionsmedicales.fr/article/36180658",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s12013-022-01102-3"
}
},
{
"@type": "ScholarlyArticle",
"name": "GRK2-mediated AKT activation controls cell cycle progression and G2 checkpoint in a p53-dependent manner.",
"datePublished": "2024-08-29",
"url": "https://questionsmedicales.fr/article/39198399",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1038/s41420-024-02143-8"
}
},
{
"@type": "ScholarlyArticle",
"name": "BI6727 and GSK461364A, potent PLK1 inhibitors induce G2/M arrest and apoptosis against cholangiocarcinoma cell lines.",
"datePublished": "2023-07-08",
"url": "https://questionsmedicales.fr/article/37454493",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.prp.2023.154678"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Maladies du système immunitaire",
"item": "https://questionsmedicales.fr/mesh/D007154"
},
{
"@type": "ListItem",
"position": 3,
"name": "Hypersensibilité",
"item": "https://questionsmedicales.fr/mesh/D006967"
},
{
"@type": "ListItem",
"position": 4,
"name": "Hypersensibilité retardée",
"item": "https://questionsmedicales.fr/mesh/D006968"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Hypersensibilité retardée - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Hypersensibilité retardée",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-14",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Hypersensibilité retardée",
"description": "Comment diagnostiquer l'hypersensibilité retardée ?\nQuels tests sont utilisés pour le diagnostic ?\nQuels signes indiquent une hypersensibilité retardée ?\nPeut-on diagnostiquer par des analyses sanguines ?\nQuel rôle joue l'historique médical dans le diagnostic ?",
"url": "https://questionsmedicales.fr/mesh/D006968?mesh_terms=G2+Phase+Cell+Cycle+Checkpoints&page=2#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Hypersensibilité retardée",
"description": "Quels sont les symptômes courants ?\nLes symptômes apparaissent-ils immédiatement ?\nY a-t-il des symptômes systémiques ?\nComment se manifeste une réaction cutanée ?\nLes symptômes varient-ils d'une personne à l'autre ?",
"url": "https://questionsmedicales.fr/mesh/D006968?mesh_terms=G2+Phase+Cell+Cycle+Checkpoints&page=2#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Hypersensibilité retardée",
"description": "Comment prévenir l'hypersensibilité retardée ?\nLes tests d'allergie aident-ils à la prévention ?\nLes changements de mode de vie sont-ils nécessaires ?\nLes médicaments préventifs sont-ils disponibles ?\nComment gérer les expositions accidentelles ?",
"url": "https://questionsmedicales.fr/mesh/D006968?mesh_terms=G2+Phase+Cell+Cycle+Checkpoints&page=2#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Hypersensibilité retardée",
"description": "Quel est le traitement principal de l'hypersensibilité retardée ?\nLes antihistaminiques sont-ils efficaces ?\nComment les corticostéroïdes aident-ils ?\nY a-t-il des traitements topiques recommandés ?\nLes traitements sont-ils différents pour les enfants ?",
"url": "https://questionsmedicales.fr/mesh/D006968?mesh_terms=G2+Phase+Cell+Cycle+Checkpoints&page=2#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Hypersensibilité retardée",
"description": "Quelles complications peuvent survenir ?\nL'hypersensibilité retardée peut-elle entraîner des maladies chroniques ?\nY a-t-il un risque d'anaphylaxie ?\nComment les complications affectent-elles la qualité de vie ?\nLes complications nécessitent-elles une hospitalisation ?",
"url": "https://questionsmedicales.fr/mesh/D006968?mesh_terms=G2+Phase+Cell+Cycle+Checkpoints&page=2#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Hypersensibilité retardée",
"description": "Quels sont les facteurs de risque principaux ?\nL'âge influence-t-il le risque d'hypersensibilité ?\nLes professions exposées sont-elles à risque ?\nLe stress peut-il aggraver l'hypersensibilité ?\nLes antécédents familiaux jouent-ils un rôle ?",
"url": "https://questionsmedicales.fr/mesh/D006968?mesh_terms=G2+Phase+Cell+Cycle+Checkpoints&page=2#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer l'hypersensibilité retardée ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic repose sur l'historique médical et des tests cutanés spécifiques."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour le diagnostic ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les tests de patch et les tests de stimulation lymphocytaire sont couramment utilisés."
}
},
{
"@type": "Question",
"name": "Quels signes indiquent une hypersensibilité retardée ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des éruptions cutanées, démangeaisons et rougeurs apparaissent après exposition à l'allergène."
}
},
{
"@type": "Question",
"name": "Peut-on diagnostiquer par des analyses sanguines ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les analyses sanguines ne sont pas spécifiques, mais peuvent aider à évaluer l'inflammation."
}
},
{
"@type": "Question",
"name": "Quel rôle joue l'historique médical dans le diagnostic ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'historique médical aide à identifier les allergènes potentiels et les antécédents d'exposition."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes courants ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent éruptions cutanées, démangeaisons, et parfois fièvre."
}
},
{
"@type": "Question",
"name": "Les symptômes apparaissent-ils immédiatement ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, ils apparaissent généralement 24 à 72 heures après l'exposition à l'allergène."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes systémiques ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes systémiques comme la fièvre ou la fatigue peuvent survenir dans certains cas."
}
},
{
"@type": "Question",
"name": "Comment se manifeste une réaction cutanée ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "La réaction cutanée se manifeste par des rougeurs, des vésicules et un gonflement localisé."
}
},
{
"@type": "Question",
"name": "Les symptômes varient-ils d'une personne à l'autre ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'intensité et la nature des symptômes peuvent varier selon les individus."
}
},
{
"@type": "Question",
"name": "Comment prévenir l'hypersensibilité retardée ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Éviter l'exposition aux allergènes connus est la meilleure méthode de prévention."
}
},
{
"@type": "Question",
"name": "Les tests d'allergie aident-ils à la prévention ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les tests d'allergie peuvent identifier les allergènes à éviter pour prévenir les réactions."
}
},
{
"@type": "Question",
"name": "Les changements de mode de vie sont-ils nécessaires ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des changements de mode de vie, comme éviter certains aliments ou produits, peuvent être nécessaires."
}
},
{
"@type": "Question",
"name": "Les médicaments préventifs sont-ils disponibles ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des antihistaminiques peuvent être pris en prévention avant une exposition connue."
}
},
{
"@type": "Question",
"name": "Comment gérer les expositions accidentelles ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Avoir un plan d'action et des médicaments d'urgence peut aider à gérer les expositions accidentelles."
}
},
{
"@type": "Question",
"name": "Quel est le traitement principal de l'hypersensibilité retardée ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le traitement principal consiste en l'évitement de l'allergène et l'utilisation de corticostéroïdes."
}
},
{
"@type": "Question",
"name": "Les antihistaminiques sont-ils efficaces ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les antihistaminiques peuvent soulager les démangeaisons, mais ne traitent pas la cause."
}
},
{
"@type": "Question",
"name": "Comment les corticostéroïdes aident-ils ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les corticostéroïdes réduisent l'inflammation et soulagent les symptômes cutanés."
}
},
{
"@type": "Question",
"name": "Y a-t-il des traitements topiques recommandés ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des crèmes ou pommades corticostéroïdes peuvent être appliquées sur les zones affectées."
}
},
{
"@type": "Question",
"name": "Les traitements sont-ils différents pour les enfants ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les traitements peuvent être adaptés en fonction de l'âge et de la gravité des symptômes."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications comme des infections cutanées peuvent survenir si les lésions sont grattées."
}
},
{
"@type": "Question",
"name": "L'hypersensibilité retardée peut-elle entraîner des maladies chroniques ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des réactions répétées peuvent contribuer à des maladies cutanées chroniques."
}
},
{
"@type": "Question",
"name": "Y a-t-il un risque d'anaphylaxie ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'anaphylaxie est rare dans l'hypersensibilité retardée, mais des réactions sévères peuvent survenir."
}
},
{
"@type": "Question",
"name": "Comment les complications affectent-elles la qualité de vie ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications peuvent entraîner des douleurs, des démangeaisons et une gêne sociale."
}
},
{
"@type": "Question",
"name": "Les complications nécessitent-elles une hospitalisation ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Dans certains cas graves, une hospitalisation peut être nécessaire pour un traitement intensif."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque principaux ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les antécédents d'allergies, l'exposition répétée et la génétique sont des facteurs de risque."
}
},
{
"@type": "Question",
"name": "L'âge influence-t-il le risque d'hypersensibilité ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les jeunes enfants et les personnes âgées peuvent être plus à risque."
}
},
{
"@type": "Question",
"name": "Les professions exposées sont-elles à risque ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines professions, comme celles en contact avec des produits chimiques, présentent un risque accru."
}
},
{
"@type": "Question",
"name": "Le stress peut-il aggraver l'hypersensibilité ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le stress peut exacerber les symptômes et augmenter la sensibilité aux allergènes."
}
},
{
"@type": "Question",
"name": "Les antécédents familiaux jouent-ils un rôle ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un historique familial d'allergies peut augmenter le risque d'hypersensibilité retardée."
}
}
]
}
]
}
Human glioblastoma multiforme (GBM) is one of the most malignant brain tumors, with a high mortality rate worldwide. Conventional GBM treatment is now challenged by the presence of the blood-brain bar...
DNA repair mechanisms keep genome integrity and limit tumor-associated alterations and heterogeneity, but on the other hand they promote tumor survival after radiation and genotoxic chemotherapies. We...
During mitosis, phosphorylation and dephosphorylation of lamins triggers the nuclear envelope disassembly/assembly. However, it hasn't been known whether lamin proteins undergo any modification other ...
Cell cycle checkpoints, activated by stressful events, halt the cell cycle progression, and prevent the transmission of damaged DNA. These checkpoints prompt cell repair but also trigger cell death if...
Polo-like kinase 1 (PLK1) is an essential mitotic checkpoint protein that plays a key role in cell cycle division. Overexpression of PLK1 has been associated with poor prognosis in various cancers. Ch...
Polo-like kinase 4 (PLK4) is a crucial regulator for centriole replication and is reported to be aberrantly expressed in various cancers, where it participates to tumorigenesis. However, PLK4 effect i...
Quantitative real-time PCR was used to measure the level of PLK4. Centrinone, a selective PLK4 small molecule inhibitor, was used for PLK4 inhibition and explore its effect in AML cells. The cell grow...
PLK4 was overexpressed in AML cells. PLK4 knockdown or its specific inhibition by centrinone induced G2/M phase arrest via suppressing the expression of cyclin B1 and Cdc2 and promoting the level of p...
These findings demonstrated that targeting PLK4 can induce apoptosis, G2/M and ER stress in AML cells....
Colorectal carcinoma (CRC) is the third most prevalent cancer, causing a significant mortality worldwide. Present available therapies are surgery, chemotherapy including radiotherapy, and these are kn...
Compromised cell-cycle checkpoint is a major obstacle for rendering radiotherapeutic success of radioresistant cells. Aspirin (ASA), an anti-inflammatory agent was repurposed previously for improving ...
Radioresistant subline SiHa/RR was developed from parental cervical squamous carcinoma cell line SiHa by chronic fractionated irradiation (IR). The radioresistance property of SiHa/RR was confirmed by...
Higher colony forming ability of SiHa/RR compared to SiHa became restrained upon ASA (5μM) treatment prior to IR. Flow cytometric analysis of ASA treated cells showed increased G2/M population followe...
This work established that G2/M arrest and mitotic catastrophe can be considered as the principle mechanism of restoration of radiosensitivity in SiHa/RR by ASA pretreatment....
The transcription factor Wilms' tumor 1 (WT1) is involved in development, tissue homeostasis, and disease. However, the exact roles and the mechanisms of WT1 in renal carcinoma are not well understood...
Overcoming multidrug resistance (MDR) represents a major obstacle in cancer chemotherapy. Cardiac glycosides (CGs) are efficient in the treatment of heart failure and recently emerged in a new role in...